The accompanying table [click to enlarge or download] includes the 36 remaining companies in the ETF Innovators [ETFI] Emerging Bio-Pharma Index with market caps between $150M-$1.5B, which were not included in the previous two articles I wrote about the group – featuring the Top 40 Rated Companies and companies below the $150M market cap cutoff.
However, several of the companies included in the remaining group of 36 have been in the news recently due to FDA related news . Late last week, Ligand Pharma (LGND) received approval along with its collaboration partner Glaxo (GSK) for Promacta while Theravance (THRX) received a positive panel review for its antibiotic telavancin. Previously, Amag Pharma (AMAG) more than doubled on word the FDA would decide on its iron-deficiency anemia drug ferumoxytol by year-end.
Last Friday, Dyax Corp. (DYAX) reported that the FDA accepted its BLA with a priority review for DX-88 (ecallantide) for the treatment of acute attacks of hereditary angioedema [HAE] with a decision date deadline in late March 2009. Savient Pharma (SVNT) expects to hear back from the FDA on its Puricase BLA before year-end on whether the agency will accept the application and designate it as a six-month priority review.
Human Genome Sciences (HGSI) is due to release Phase 3 results before year-end for hepatitis C drug Albuferon with the stock trading near all-time lows below 2 bucks and far from the triple digit share price achieved during the biotech madness around the year 2000 – check out this Seeking Alpha article for a summary of the situation since I do not follow the stock.
Alnylam (ALNY) is trading well off its highs by about 50% at near two-year lows with a bullish outlook based on its RNA interference [RNAi] drug discovery platform and extensive early stage pipeline, which Merck (MRK) paid $1.1B two years ago for a similar RNAi drug discovery company, Sirna Therapeutics.
$18.18 (11/23/08)
